Combination therapies of HDAC inhibitors and PD-1 inhibitors
US10385130B2 · kind B2 · utility
2Cited by
109References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 11, 2017 |
| Grant date | Aug 20, 2019 |
| Priority date | — |
| Expiry date | May 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.